Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2005;97:e88-e96
Published online before print October 13, 2005, doi: 10.1161/01.RES.0000190400.46267.7e
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
97/9/e88    most recent
01.RES.0000190400.46267.7ev1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takata, Y.
Right arrow Articles by Hsueh, W. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takata, Y.
Right arrow Articles by Hsueh, W. A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CHOLESTEROL
Related Collections
Right arrow Gene regulation
Right arrow Mechanism of atherosclerosis/growth factors
(Circulation Research. 2005;97:e88.)
© 2005 American Heart Association, Inc.


UltraRapid Communication

Transcriptional Repression of ATP-Binding Cassette Transporter A1 Gene in Macrophages

A Novel Atherosclerotic Effect of Angiotensin II

Yasunori Takata, Van Chu, Alan R. Collins, Christopher J. Lyon, Wei Wang, Florian Blaschke, Dennis Bruemmer, Evren Caglayan, William Daley, Jitsuo Higaki, Michael C. Fishbein, Rajendra K. Tangirala, Ronald E. Law, Willa A. Hsueh

From the Division of Endocrinology, Diabetes, and Hypertension (Y.T., V.C., A.R.C., C.J.L., W.W., F.B., D.B., E.C., R.K.T., R.E.L., W.A.H.) and the Department of Pathology (M.C.F.), David Geffen School of Medicine, University of California, Los Angeles; Second Department of Internal Medicine (Y.T., J.H.), Ehime University School of Medicine, Japan; Division of Endocrinology and Molecular Medicine (D.B.), University of Kentucky College of Medicine, Lexington; Novartis Pharmaceuticals Corporation (W.D.), East Hanover, NJ; and Takeda Pharmaceuticals North America (R.E.L.), Lincolnshire, Ill.

Correspondence to Willa A. Hsueh, MD, Division of Endocrinology, Diabetes, and Hypertension, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095. E-mail whsueh{at}mednet.ucla.edu

Angiotensin II (Ang II) is a powerful accelerator of atherosclerosis. Herein, we describe a novel transcription mechanism through which Ang II inhibits macrophage expression of the ATP-binding cassette transporter A1 (ABCA1), a key regulator of reverse cholesterol transport. We demonstrate that chronic Ang II infusion substantially promotes macrophage infiltration, foam cell formation, and atherosclerosis in low-density lipoprotein receptor-deficient mice and significantly reduces ABCA1 expression in peripheral macrophages. Administration of the Ang II type 1 receptor blocker valsartan inhibited Ang II-induced ABCA1 mRNA repression, macrophage cholesterol accumulation, and atherosclerosis. Ang II treatment reduced ABCA1 promoter activity of in vitro cultured mouse peritoneal macrophages, inducing fos-related antigen 2 (Fra2) protein binding to an ABCA1 promoter E-box motif, a site known to negatively regulate macrophage ABCA1 transcription. Valsartan pretreatment blocked Fra2 binding to the ABCA1 promoter, and Fra2 small interfering RNA pretreatment attenuated Ang II-mediated ABCA1 transcriptional inhibition, confirming the role of Fra2 in this process. This new evidence suggests that Ang II, a well-known proinflammatory and pro-oxidative factor, alters macrophage cholesterol homeostasis by repressing ABCA1 to promote foam cell formation and atherosclerosis.


Key Words: angiotensin II • ATP-binding cassette transporter A1 • macrophage cholesterol accumulation • fos-related antigen 2




This article has been cited by other articles:


Home page
HypertensionHome page
K. Kappert, O. Tsuprykov, J. Kaufmann, J. Fritzsche, I. Ott, M. Goebel, I. N. Bahr, P.-L. Hassle, R. Gust, E. Fleck, et al.
Chronic Treatment With Losartan Results in Sufficient Serum Levels of the Metabolite EXP3179 for PPAR{gamma} Activation
Hypertension, October 1, 2009; 54(4): 738 - 743.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
Y. Zuo, P. Yancey, I. Castro, W. Khan, M. Motojima, I. Ichikawa, A. B. Fogo, M. F. Linton, S. Fazio, and V. Kon
Renal Dysfunction Potentiates Foam Cell Formation by Repressing ABCA1
Arterioscler Thromb Vasc Biol, September 1, 2009; 29(9): 1277 - 1282.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
K.-H. Su, J.-Y. Tsai, Y. R. Kou, A.-N. Chiang, S.-H. Hsiao, Y.-L. Wu, H.-H. Hou, C.-C. Pan, S.-K. Shyue, and T.-S. Lee
Valsartan regulates the interaction of angiotensin II type 1 receptor and endothelial nitric oxide synthase via Src/PI3K/Akt signalling
Cardiovasc Res, June 1, 2009; 82(3): 468 - 475.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
S. Van Linthout, F. Spillmann, M. Lorenz, M. Meloni, F. Jacobs, M. Egorova, V. Stangl, B. De Geest, H.-P. Schultheiss, and C. Tschope
Vascular-Protective Effects of High-Density Lipoprotein Include the Downregulation of the Angiotensin II Type 1 Receptor
Hypertension, April 1, 2009; 53(4): 682 - 687.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
E. Caglayan, B. Stauber, A. R. Collins, C. J. Lyon, F. Yin, J. Liu, S. Rosenkranz, E. Erdmann, L. E. Peterson, R. S. Ross, et al.
Differential Roles of Cardiomyocyte and Macrophage Peroxisome Proliferator-Activated Receptor {gamma} in Cardiac Fibrosis
Diabetes, September 1, 2008; 57(9): 2470 - 2479.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
Y. Takata, J. Liu, F. Yin, A. R. Collins, C. J. Lyon, C.-H. Lee, A. R. Atkins, M. Downes, G. D. Barish, R. M. Evans, et al.
PPAR{delta}-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis
PNAS, March 18, 2008; 105(11): 4277 - 4282.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
Y. Takata, H. Osawa, M. Kurata, M. Kurokawa, J. Yamauchi, M. Ochi, W. Nishida, T. Okura, J. Higaki, and H. Makino
Hyperresistinemia Is Associated With Coexistence of Hypertension and Type 2 Diabetes
Hypertension, February 1, 2008; 51(2): 534 - 539.
[Abstract] [Full Text] [PDF]